1. Home
  2. ERAS vs TTI Comparison

ERAS vs TTI Comparison

Compare ERAS & TTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERAS
  • TTI
  • Stock Information
  • Founded
  • ERAS 2018
  • TTI 1981
  • Country
  • ERAS United States
  • TTI United States
  • Employees
  • ERAS N/A
  • TTI N/A
  • Industry
  • ERAS Biotechnology: Pharmaceutical Preparations
  • TTI Oil & Gas Production
  • Sector
  • ERAS Health Care
  • TTI Energy
  • Exchange
  • ERAS Nasdaq
  • TTI Nasdaq
  • Market Cap
  • ERAS 348.4M
  • TTI 363.3M
  • IPO Year
  • ERAS 2021
  • TTI 1990
  • Fundamental
  • Price
  • ERAS $1.36
  • TTI $2.80
  • Analyst Decision
  • ERAS Strong Buy
  • TTI Strong Buy
  • Analyst Count
  • ERAS 6
  • TTI 2
  • Target Price
  • ERAS $4.83
  • TTI $5.25
  • AVG Volume (30 Days)
  • ERAS 1.5M
  • TTI 1.2M
  • Earning Date
  • ERAS 05-13-2025
  • TTI 04-29-2025
  • Dividend Yield
  • ERAS N/A
  • TTI N/A
  • EPS Growth
  • ERAS N/A
  • TTI 426.72
  • EPS
  • ERAS N/A
  • TTI 0.84
  • Revenue
  • ERAS N/A
  • TTI $605,279,000.00
  • Revenue This Year
  • ERAS N/A
  • TTI $2.67
  • Revenue Next Year
  • ERAS N/A
  • TTI $7.55
  • P/E Ratio
  • ERAS N/A
  • TTI $3.05
  • Revenue Growth
  • ERAS N/A
  • TTI N/A
  • 52 Week Low
  • ERAS $1.01
  • TTI $2.03
  • 52 Week High
  • ERAS $3.45
  • TTI $5.12
  • Technical
  • Relative Strength Index (RSI)
  • ERAS 54.43
  • TTI 47.64
  • Support Level
  • ERAS $1.06
  • TTI $2.65
  • Resistance Level
  • ERAS $1.47
  • TTI $2.82
  • Average True Range (ATR)
  • ERAS 0.14
  • TTI 0.10
  • MACD
  • ERAS 0.02
  • TTI -0.01
  • Stochastic Oscillator
  • ERAS 70.65
  • TTI 28.23

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About TTI Tetra Technologies Inc.

Tetra Technologies Inc is a diversified oil and gas services company, focused on completion fluids and associated products and services, water management, frac flowback, production well testing, offshore rig cooling, and compression services. It has two reporting segments namely Completion Fluids & Products, and Water & Flowback Services. The Completion Fluids & Products Division manufactures and markets clear brine fluids, additives, and associated products and services. Majority of revenue is from Completion Fluids & Products. The company derives maximum revenue from United states.

Share on Social Networks: